Derazantinib - Basilea Pharmaceutica

Drug Profile

Derazantinib - Basilea Pharmaceutica

Alternative Names: ARQ-087; BAL 087

Latest Information Update: 22 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ArQule
  • Class Amines; Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma
  • Phase I Solid tumours

Most Recent Events

  • 14 Aug 2018 Basilea plans a phase II trial for Solid tumours, in mid of 2019
  • 24 Jun 2018 Biomarkers information updated
  • 17 Apr 2018 Basilea receives license from ArQule to develop and commercialise derazantinib in World excluding the People’s Republic of China, Hong Kong, Macau and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top